Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 633 | 98 | 526 |
| Samples | 576 | 94 | 473 |
| Peptides | 443 | 64 | 386 |
Function
NPR1 · Natriuretic peptide receptor 1
Guanylyl cyclases, catalyzing the production of cGMP from GTP, are classified as soluble and membrane forms (Garbers and Lowe, 1994 [PubMed 7982997]). The membrane guanylyl cyclases, often termed guanylyl cyclases A through F, form a family of cell-surface receptors with a similar topographic structure: an extracellular ligand-binding domain, a single membrane-spanning domain, and an intracellular region that contains a protein kinase-like domain and a cyclase catalytic domain. GC-A and GC-B function as receptors for natriuretic peptides; they are also referred to as atrial natriuretic peptide receptor A (NPR1) and type B (NPR2; MIM 108961). Also see NPR3 (MIM 108962), which encodes a protein with only the ligand-binding transmembrane and 37-amino acid cytoplasmic domains. NPR1 is a membrane-bound guanylate cyclase that serves as the receptor for both atrial and brain natriuretic peptides (ANP (MIM 108780) and BNP (MIM 600295), respectively).[supplied by OMIM, May 2009].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000368680 | P16066 | 633 | 443 |
Gene Properties
Recurrent Mutations
All 443 amino-acid changes on canonical ENST00000368680 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in NPR1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in NPR1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 5/40 12% | 0/0 0% |
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Endometrial Carcinoma | 8/42 19% | 23/612 4% |
| Hodgkins Lymphoma | 3/16 19% | 3/122 2% |
| Glioblastoma | 4/98 4% | 0/0 0% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Melanoma | 6/210 3% | 59/1899 3% |
| Other Solid Cancers | 2/94 2% | 39/1515 3% |
| Colorectal Carcinoma | 9/143 6% | 64/3239 2% |
| Gastric Carcinoma | 4/74 5% | 36/1809 2% |
| Small Cell Lung Carcinoma | 5/9 56% | 11/752 1% |
| Non-Small Cell Lung Carcinoma | 11/304 4% | 23/1390 2% |
| Germ Cell Tumour | 2/25 8% | 1/169 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 25/1592 2% |
| Bladder Carcinoma | 0/58 0% | 14/956 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 11/810 1% |
| Neuroendocrine Tumour | 5/154 3% | 4/577 1% |
| Hepatocellular Carcinoma | 2/46 4% | 25/2210 1% |
| Non-Cancerous | 1/104 1% | 9/830 1% |
| Biliary Tract Carcinoma | 0/54 0% | 10/950 1% |
| Osteosarcoma | 2/45 4% | 0/166 0% |
| Esophageal Squamous Cell Carcinoma | 3/51 6% | 20/2550 1% |
| Cervical Carcinoma | 0/35 0% | 4/422 1% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| Glioma | 0/52 0% | 19/2127 1% |
| Esophageal Carcinoma | 0/23 0% | 6/769 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Breast Carcinoma | 7/144 5% | 18/3264 1% |
| Other Sarcomas | 3/69 4% | 2/699 0% |
| Ovarian Carcinoma | 2/109 2% | 5/998 0% |
Mutation Distribution
Where NPR1 is mutated · all tissues, split by cell line vs tissue
How many mutations in NPR1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 633 mutations in NPR1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|